Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$173.34MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Charles Bachtell
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2,900
- Beta
- 1.72
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.77
Financials
Revenue
$173.34M+7770.1%Net Income
$16.80MEBITDA
$26.54MFree Cash Flow
$5.90M+2150774.7%EPS (diluted)
$0.04Shares Outstanding (diluted)
472.32M+1356957.6%Operating Expenses
$73.59MCash & Debt
$32.87MReturn of Capital
$0.00Revenue by Segment (annual)
$655.85MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $667.33M | $-137.78M | $-0.39 |
| 2024 | $724.34M | $-74.44M | $-0.22 |
| 2023 | $770.88M | $-175.52M | $-0.54 |
| 2022 | $842.68M | $-212.05M | $-0.71 |
| 2021 | $821.68M | $-319.60M | $-1.22 |
| 2020 | $476.25M | $-102.16M | $-0.49 |
| 2019 | $128.53M | $-43.20M | $-0.37 |
| 2018 | $43.25M | $-1.92M | $-0.03 |
| 2017 | $10.31M | $-85.8K | $-2.63 |
| 2016 | $0.00 | $-108.6K | $-3.10 |
| 2015 | $0.00 | $47.4K | $1.16 |
| 2014 | $0.00 | $-117.4K | $-3.38 |
| 2013 | $0.00 | $-202.7K | $-5.82 |
| 2012 | $0.00 | $-361.4K | $-10.38 |
Valuation
CRLBFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsbusinesswire.com·19d ago·Neutral
Cresco Labs Appoints Edward Tilly to Board of Directors CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced the appointment of Edward Tilly to its Board of Directors, effective September 18, 2026. Mr. Tilly will serve as an independent director and join the Audit Committee, bring…
View source ↗ - Newsbusinesswire.com·34d ago·Negative
…co Labs Acquires Nine Pennsylvania Dispensaries in Accretive Transaction to Strengthen Market Leadership CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”). The Transaction consists of nine operational retail medical marijuana dispensaries i…
View source ↗ - Newsmarijuanastocks.com·54d ago·Neutral
3 Marijuana Stocks For Investors To Consider What will help marijuana stock investors trade more, even in the midst of laws changing in the USA? It is no secret that nothing has moved pot stocks more than news of global reform or regulatory matters. For the US, what happens at the federal level has moved the needle the most, with the recent passing of legislation to reclassify cannabis to Schedule 3.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.02 per share
Typical surprise -33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.04 vs $-0.02beat
- Fri, May 8$-0.04 vs $-0.03miss
- Thu, Mar 5$-0.24 vs $-0.01miss
- Wed, Nov 5$-0.05 vs $-0.03miss
- Thu, Aug 7$-0.05 vs $-0.04miss
- Fri, May 30$-0.04 vs $-0.03miss
Estimates and results for CRLBF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in CRLBF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.